[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 21, 2001

Industry-Sponsored Grand Rounds and Prescribing Behavior

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(11):1443-1444. doi:10.1001/jama.285.11.1443

To the Editor: We recently discovered a sudden and sustained 3-fold increase in the pharmacy expenditures for quetiapine fumarate, an atypical antipsychotic agent, at the Minneapolis Veterans Affairs Medical Center (VAMC). This occurred in April 2000, which was 28 months after the drug became available in the United States and 5 months after it was placed on the hospital formulary. We investigated this sudden and dramatic increase in prescription costs for this drug at our institution.

First Page Preview View Large
First page PDF preview
First page PDF preview
×